Targanta Therapeutics Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections (cSSSI)

WASHINGTON--(BUSINESS WIRE)--Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of key clinical findings of its lead antibiotic drug candidate, oritavancin, at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC. The presentations highlight the efficacy and safety results of two Phase 3 clinical studies of oritavancin.